SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
PRAX

Praxis Precision Medicines, Inc (PRAX)

NASDAQ: PRAX · Real-Time Price · USD
Healthcare · Biotechnology
$305.06-$5.21 (-1.68%)
 
Market cap
$8.53B
Insider Score
Analyst consensus
Market Cap$8.53B+57.0%
Revenue (ttm)n/a
Net Income-$359.43M
EPS-$12.82
Shares Out27.95M
PE Ration/a
Forward PE-31.09
Dividendn/a
Ex-Dividend Daten/a
Volume836,922
Open$315.74
Previous Close$310.27
Day's Range$300.99 - $319.00
52-Week Range$160.11 - $392.70
Beta2.84
AnalystsStrong Buy
Price Target$674.48(+121.10%)
Earnings DateNov 9, 2026

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Address
99 High Street, Boston, MA, 02110, United States
Market Cap
8.53 billion
Employees
168
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$3.61M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-5.44%
5 Days
-6.82%
1 Month
+28.34%
6 Months
-3.20%
1 Year
+57.04%

$PRAX stock is featured in our Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of PRAX by members of U.S. Congress

Gilbert CisnerosHouse / DPurchase$1.00K – $15.00KSep 29, 2026
Gilbert CisnerosHouse / DPurchase$1.00K – $15.00KJul 30, 2026
Gilbert Ray CisnerosHouse / DPurchase$1.00K – $15.00KJul 30, 2026
Gilbert Ray CisnerosHouse / DPurchase$1.00K – $15.00KJul 29, 2026

Recently reported changes in PRAX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by PRAX's directors and management

Net Shares Purchased by Insiders−20k−10k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

PRAX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New PRAX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to PRAX from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from PRAX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
78

News check: Multiple analyst upgrades and price target increases alongside FDA milestone announcements for lead drug candidates create solidly bullish coverage.

Recent Insider Activity

Buys
0
Sells
12
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IBRNiShares Neuroscience and Healthcare ETF4.30%
GNOMGlobal X - Genomics & Biotechnology ETF3.03%
TDNAT. Rowe Price Biotech ETF2.26%
LFSCF/M Emerald Life Sciences Innovation ETF2.23%
XBIState Street SPDR S&P Biotech ETF1.41%
GURUGlobal X - Guru Index ETF1.28%
HELXFranklin Genomic Advancements ETF1.18%
PCSGPolen 5Perspectives Small-Mid Growth ETF1.15%
WDNAWisdomTree BioRevolution Fund1.05%
MMSCFirst Trust Multi-Manager Small Cap Opportunities ETF1.02%
BBCVirtus Biotech Clinical Trials ETF0.96%
MEDIHarbor Health Care ETF (MEDI)0.93%

Weight is the stock’s share of each fund’s holdings.